All News
Achieving MDA in PsA results in improvements in disease activity measures, PROMs and maintenance of therapy. It may help increased work productivity
and reductions in lost wages in PsA @RheumNow #ACR21 Abst#1344 https://t.co/KR1DPXt7jh https://t.co/3bfeiXxN54
Dr. Antoni Chan synovialjoints ( View Tweet)
Multinational web survey (UPLIFT) showing patients with PsA➕ active PsO associated with - more active disease; 🔼prevalence comorbidities ; depression
⭐️Positive depression screen associated with overall disease impact as measured by PsAID
Abst#1351 #ACR21 @RheumNow https://t.co/w1JETzNao9
swethaann23 swethaann23 ( View Tweet)
#ACR21 #Abstr1425 Interim AURORA2 (Extension of original RCT to 2 years) showed #lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs. No unexpected safety signals @RheumNow https://t.co/aclJZNOGc5 https://t.co/ENl9SzMHN3
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How much PNL do you need with TCZ in GCA, to avoid early risks of visual loss?
GiACTA: 26w. Can we do better?
GUSTO: 3d pulse IVMP. Not enough.
Is 8w the sweet spot?🤔
sustained remission off PNL at 52w: 20/27
no visual loss/ischaemia
@MGHrheumatology #ACR21 ABST1413 @RheumNow https://t.co/IV9MorvTeW
David Liew drdavidliew ( View Tweet)
#Voclosporin still going strong in LTE in #lupus nephritis AURORA 2. No new safety signals, stable GFR. Cost may be problem! Abst#1425 #ACR21 #ACRBest @RheumNow https://t.co/biEptZbJoz
Janet Pope Janetbirdope ( View Tweet)
#ACR21 Abs#1426 - VEXAS!
Predictors of mortality:
▶️p.MetVal41 genotype (HR 3.5)
▶️Absence of ear chondritis (HR 3.8)
▶️Transfusion dependence (HR 2.6)
@Rheumnow https://t.co/m5bl9Ho163 https://t.co/LSNcF6EZHv
Links:
Eric Dein ericdeinmd ( View Tweet)
Abst1338 #acr21 @RheumNow BE ACTIVE Bimekizumab in 206 PsA:
Over half of TNFi-n pts achieved ACR50
resolution of dactylitis (70.2% NRI; 100.0% OC) & enthesitis (60.7% NRI; 80.6% OC)
PASI100 at Wks 48/152 63.3/58.7%
Low serious infect, mild/moderate candida. 1 microscopic colitis https://t.co/CJXyywZYJd
Olga Petryna DrPetryna ( View Tweet)
Abstr 1044
Anastasiou & colleagues examined Rx of inappropriate medications in elderly patients with rheumatic disease (RD)
- 40% RD patients received inappropriate meds
- Elderly living in areas of low SES likely to receive opioid Rx
#ACR21 @RheumNow #BeersCriteria https://t.co/fxBGVAtt1L
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR21 #Abstr1426 VEXAS is only recently described but a study in 83 patients showed importance of genotyping + clinical in predicting mortality:
💠p.Met41Val (OR: 2.6)
💠Transfusion dependent (4.5)
💠Ear chondritis protective (0.3)
@RheumNow #ACRBest https://t.co/RQwONf2MJT https://t.co/VLWRGKWmQs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The VEXAS story developing and becoming clearer...
with high mortality genotype-phenotype linked
genotype at risk for mortality (p.Met41Val)
- smaller residual UBA1b expression
- less RP
- more fever
wonderful from @maferradastrong
#ACR21 ABST1426 @RheumNow @RP_Organization https://t.co/vELXprUrPh
David Liew drdavidliew ( View Tweet)
Voclosporin for lupus nephritis maintained reductions in proteinuria. No change in eGFR at 30 months of treatment
(AURORA 2 study)
Abs#1425
#ACR21
@RheumNow https://t.co/1y9oSVXzD8
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abs#1427- Statin Use in RA
⭐️# needed to treat: 42 pts all-cause mortality
⭐️NNT 102 pts CVD events
⭐️# needed to harm: 127 pts T2DM (mild ⬆️ risk)
▶️Statin use: mortality benefit better than gen pop, CVD&DM similar effects to gen pop
@Rheumnow https://t.co/m5bl9Ho163 https://t.co/hijxbcVBzA
Links:
Eric Dein ericdeinmd ( View Tweet)
I've written more about these really useful data here for @RheumNow:
https://t.co/3dQteFr9qZ
#ACR21 @earlyarthritis @BykerkVivian https://t.co/7HufoWVtCK
Links:
David Liew drdavidliew ( View Tweet)
AURORA 2 (A2): SLE + LN
AURORA 1: Adding Voclosporin to MMF + Steroids ⬆️complete renal response by 18% @ 52w
A2: @ 30 months
💠Maintained mean GFR
💠Maintained reductions in proteinuria
💠Further safety/efficacy data to follow
https://t.co/wSvQvueKi7
#ACR2021 Abst#1425 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Median survival for pts w/#VEXAS➡️10 years
Predictors of mortality w/VEXAS:
👉p.MetVal mutation HR 3.5 (95%CI, 1.4-8.5)
👉transfusion dependency HR 2.59 (95%CI, 0.94-7.09)
👉⬇️risk w/ear chondritis HR 0.26 (95%CI,0.09-0.6)
@marcelaferrada #ACR21 @rheumnow Abstr#1426 #ACRbest
TheDaoIndex KDAO2011 ( View Tweet)
Plenary on VEXAS - good over view of VEXAS and why important to Rheums #ACR21 Abstract# 1426 https://t.co/jx0mQNlfwK
Dr. John Cush RheumNow ( View Tweet)
SLE Panel: Learning about Lupus at #ACR21
Drs. Kathryn Dao ( @KDAO2011) , Janet Pope ( @Janetbirdope) Yuz Yusof ( @Yuz6Yusof) Bella Mehta ( @bella_mehta) and Pedro Castillo ( @_Castillo_Pedro) discuss lupus-related data presented Saturday.
https://t.co/h0vPIwUeOz https://t.co/eJDtRKPdYT
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Pearl from Dr. @JKolfenbach
"Sometimes, taking off the mask is worth it" during physical exam:
➡️Strawberry gums in GPA
➡️Drug-induced gingival hyperplasia
‣ i.e. cyclosporine, CCB
➡️Tongue necrosis in GCA
➡️Ovoidal palatal patch in TIF1gamma DM
#ACR21 @RheumNow https://t.co/H98bTLLse6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Wonderful overview of myositis autoantibodies to reference from the Rheum Secrets & Pearls session by Dr. @JKolfenbach & Dr. John Stone at #ACR21 that can be accessed on-demand now!
@RheumNow https://t.co/H6N02MzFSu
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr1423 Munroe & James developed a novel #Lupus Classification Risk Immune Index using either 9 or 32 soluble mediators from sera. This index could predict transition to meeting classification criteria (with or without autoantibodies) @RheumNow https://t.co/Kr9fWaoW1L https://t.co/8wkgrzeRnt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)